Efficacy

Introduction to Tagrisso (Osimertinib)

Tagrisso (osimertinib) is a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) designed to inhibit both EGFR-sensitizing and EGFR T790M resistance mutations, with activity against central nervous system metastases. It is specifically indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR T790M mutation, as detected by an FDA-approved test. The efficacy of Tagrisso in lung cancer treatment has been demonstrated in several clinical trials, leading to its approval and widespread use in this indication.

Efficacy of Tagrisso in Lung Cancer

Several clinical trials have established the efficacy of Tagrisso in treating NSCLC. In the AURA3 study, Tagrisso significantly improved progression-free survival (PFS) compared to platinum-based chemotherapy in patients with T790M mutation-positive advanced NSCLC who had disease progression after first-line EGFR-TKI therapy. The median PFS was substantially longer for patients receiving Tagrisso than for those receiving chemotherapy. Additionally, Tagrisso has shown a higher objective response rate (ORR) and better control of central nervous system metastases compared to standard chemotherapy in this patient population.

Introduction to Cyramza (Ramucirumab)

Cyramza (ramucirumab) is a vascular endothelial growth factor receptor 2 (VEGFR2) antagonist used in the treatment of various cancers, including NSCLC. It is indicated for use in combination with docetaxel in patients with metastatic NSCLC with disease progression on or after platinum-based chemotherapy. Patients with EGFR or anaplastic lymphoma kinase (ALK) genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving Cyramza.

Efficacy of Cyramza in Lung Cancer

The efficacy of Cyramza in lung cancer was demonstrated in the REVEL trial, a randomized, double-blind, placebo-controlled study. In this trial, patients with metastatic NSCLC who had progressed during or after platinum-based chemotherapy were treated with Cyramza plus docetaxel or placebo plus docetaxel. Results showed a statistically significant improvement in overall survival for patients receiving the Cyramza combination compared to those receiving the placebo combination. Additionally, there was an improvement in PFS and ORR in the Cyramza group. These results support the use of Cyramza in combination with docetaxel as a treatment option for patients with metastatic NSCLC after the failure of prior platinum-based chemotherapy.